Court denies Teva exclusivity for generic Risperdal

NEW YORK Teva will not get market exclusivity for a generic version of Johnson & Johnson’s antipsychotic drug Risperdal, a United States district court has ruled.

The U.S. Court of Appeals for the District of Columbia issued the ruling Friday, prompting the Israeli generic drug maker to seek a stay of the decision. The company had received market exclusivity in a ruling in April.

Teva began marketing the generic Risperdal (risperidone) in June. The Food and Drug Administration gives 180 days of market exclusivity to the first company to get approval for a generic version of a branded drug.